SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt gets US FDA tentative approval for Olopatadine

01 Jul 2011 Evaluate

Drug firm Wockhardt has received tentative approval from US Food and Drug Administration (USFDA) for marketing 0.1% solution of Olopatadine hydrochloride eye drops, which is used for allergic conjunctivitis. Olopatadine is the generic name for the brand Patanol, marketed in the US by Alcon laboratories Inc, now a subsidiary of Novartis AG.

The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same.

Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalization and biotechnology. The company has a market capitalization of over $1 billion and an annual turnover of $650 million.

Wockhardt Share Price

1938.75 -134.20 (-6.47%)
05-Jun-2026 10:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1792.00
Dr. Reddys Lab 1272.50
Cipla 1391.10
Zydus Lifesciences 1091.20
Lupin 2277.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×